The motor features of Parkinson's disease (PD) are well known to manifest only when striatal
dopaminergic deficit reaches 60–70%. Thus, PD has a long pre-symptomatic and pre-motor …

Levodopa-induced motor complications are a common source of disability for patients with
Parkinson's disease. Evidence suggests that motor complications are associated with non …

The striatum is widely viewed as the fulcrum of pathophysiology in Parkinson's disease (PD)
and L-DOPA-induced dyskinesia (LID). In these disease states, the balance in activity of …

The symptoms of Parkinson's disease (PD) appear only after substantial degeneration of the
dopaminergic neuron system (eg an 80% depletion of striatal dopamine)–that is, there is a …

Scope The accumulation of misfolded α‐synuclein in dopaminergic neurons is the leading
cause of Parkinson's disease (PD). Resveratrol (RV), a polyphenolic compound derived …

The fight against neurodegenerative diseases, Alzheimer disease and Parkinson's disease
(PD), is a challenge of the 21st century. The low efficacy of treating patients is due to the late …

Rats with unilateral depletion of striatal dopamine (DA) show marked preferential use of the
ipsilateral forelimb. Previous studies have shown that implementation of motor therapy after …

Pathological and neuroimaging studies have shown that in Parkinson's disease (PD) there
is a “subclinical” or “premotor” period during which dopaminergic neurons in the substantia …

This paper provides an overview of the compensatory mechanisms which come into action
during experimental and human parkinsonism. The intrinsic properties of the dopaminergic …

Evidence suggests that following injury the brain has the capacity for self-repair and that this
can be promoted through a variety of experiences including motor activity. In their article …